introductionrapid
transmiss
noroviru
often
occur
due
low
infecti
dosag
high
genet
divers
short
incub
time
virus
caus
acut
gastroenter
may
lead
death
present
effect
vaccin
select
drug
accept
unit
state
food
drug
administr
fda
avail
treatment
noroviru
advanc
develop
noroviru
replicon
cell
line
hunov
strain
human
b
cell
murin
gnotobiot
pig
noroviru
model
facilit
discoveri
effect
small
molecul
inhibitor
vitro
vivo
area
coveredthi
review
give
brief
discuss
biolog
replic
noroviru
highlight
discoveri
antinoroviru
molecul
articl
coverag
includ
overview
current
state
noroviru
drug
discoveri
target
noroviru
life
cycl
inhibit
structur
nonstructur
protein
noroviru
proteas
polymeras
blockag
viru
entri
host
cell
final
antinoroviru
drug
clinic
develop
stage
describ
expert
opinionth
current
approach
counteract
noroviru
focus
inhibit
viral
rna
polymeras
noroviru
proteas
structur
protein
well
blockad
noroviru
entri
broadspectrum
antinoroviru
molecul
base
inhibit
proteas
develop
host
factor
way
overcom
develop
resist
mutat
also
examin
dual
approach
target
viral
host
factor
may
lead
effect
counteract
noroviru
infect
current
success
develop
noroviru
replicon
harbor
cell
noroviru
infect
human
cell
well
murin
noroviru
model
anim
model
piglet
facilit
discoveri
effect
drug
help
understand
mechan
action
norovirus
belong
famili
calicivirida
current
recogn
lead
pathogen
caus
acut
gastroenter
among
age
worldwid
unit
state
noroviru
associ
gastroenter
account
million
case
hospit
death
everi
year
moreov
norovirus
consid
major
pathogen
respons
sever
childhood
diarrhea
rotaviru
still
one
top
caus
death
children
develop
countri
death
estim
children
age
less
five
year
result
diarrhea
associ
noroviru
infect
everi
year
consid
overal
impact
term
fatal
suffer
econom
loss
disrupt
servic
noroviru
infect
estim
result
loss
billion
per
year
gener
gastroenter
caus
noroviru
acut
selflimit
among
healthi
adult
infant
elderli
immunocompromis
patient
may
sever
prolong
result
signific
morbid
mortal
efficaci
antivir
drug
usual
take
hour
sinc
durat
noroviru
ill
last
around
four
five
day
effect
drug
treatment
would
benefici
noroviru
outbreak
usual
occur
semiclos
environ
cruis
ship
nurs
home
school
hospit
person
person
transmiss
favor
often
difficult
control
due
factor
high
genet
divers
norovirus
short
incub
time
long
persist
environ
well
low
infecti
dose
virion
suffici
infect
despit
signific
econom
health
impact
norovirus
effect
vaccin
antinoroviru
drug
approv
fda
treatment
prophylact
purpos
studi
carri
identifi
potenti
vaccin
candid
norovirus
use
hunov
viruslik
particl
vlp
one
doubl
blind
studi
perform
noroviru
strain
found
vaccin
result
less
frequent
vomit
diarrhea
associ
infect
group
compar
control
group
recent
advanc
achiev
field
develop
noroviru
replicon
cell
line
murin
noroviru
mnv
enabl
search
effect
small
molecul
inhibitor
vitro
vivo
norovirus
previous
difficult
cultiv
human
norovirus
hnv
cell
system
howev
replicon
cell
system
mnv
share
mani
biolog
properti
hnv
replic
cell
cultur
provid
feasibl
small
anim
model
hnv
infect
recent
protocol
cultur
hunov
strain
directli
human
b
cell
inform
variabl
contribut
effici
viral
replic
report
though
achiev
modest
level
viral
replic
current
state
success
demonstr
first
cultiv
system
noroviru
may
provid
insight
identif
host
viral
factor
contribut
noroviru
replic
therebi
facilit
develop
effect
antinoroviru
therapeut
herein
review
highlight
recent
effort
discoveri
activ
molecul
noroviru
infect
well
current
tool
util
futur
direct
area
norovirus
small
nonenvelop
singl
strand
posit
sens
rna
virus
nm
diamet
belong
genu
noroviru
famili
calicivirida
famili
calicivirida
compris
four
genera
call
sapoviru
lagoviru
vesiviru
neboviru
virus
noroviru
sapoviru
genera
caus
acut
gastroenter
human
anim
base
molecular
character
major
viral
capsid
gene
norovirus
divid
five
genogroup
gi
gv
share
greater
amino
acid
ident
protein
norovirus
caus
gastroenter
human
belong
genogroup
gi
ii
iv
subdivid
genotyp
share
greater
ident
amino
acid
sequenc
virus
gii
group
common
sub
variant
associ
recent
major
noroviru
outbreak
singlestrand
rna
genom
kb
norovirus
coval
link
viral
protein
call
vpg
end
polyadenyl
end
noroviru
genom
organ
three
open
read
frame
figur
encod
polyprotein
cleav
virusencod
cystein
proteas
gener
six
nonstructur
protein
protein
ntpaserna
helicas
vpg
viral
proteas
viral
rna
depend
rna
polymeras
rdrp
encod
major
structur
protein
noroviru
capsid
protein
encod
small
basic
protein
present
one
two
copi
per
virion
factor
rapid
evolut
gener
new
antigen
variant
noroviru
led
increas
genet
divers
norovirus
result
rapid
emerg
new
strain
capabl
evad
antivir
drug
understand
mechan
noroviru
life
cycl
viral
replic
process
assist
design
optim
select
antinoroviru
therapeut
first
step
noroviru
life
cycl
involv
attach
virion
host
cell
surfac
receptor
individu
oligosaccharid
residu
human
histoblood
group
antigen
hbga
sialic
acid
moieti
glycolipid
heparan
sulfat
interact
subdomain
protein
viru
detail
descript
noroviru
entri
interact
human
noroviru
cell
surfac
receptor
describ
studi
perform
mnv
shown
noroviru
enter
cell
ph
independ
nonclathrin
noncaveolin
mediat
endocyt
pathway
depend
cholesterol
upon
entri
cytoplasm
viral
genom
uncoat
behav
mrna
templat
viral
rna
translat
prepackag
nonstructur
protein
vpg
mediat
translat
viral
rna
genom
larg
polyprotein
matur
polyprotein
process
viru
releas
number
nonstructur
protein
ntp
vpg
rdrp
replic
noroviru
believ
occur
replic
complex
rc
form
recruit
host
membran
endoplasm
reticulum
golgi
endosom
viral
nonstructur
protein
rc
membran
structur
contain
viral
nonstructur
protein
viral
rna
genom
host
cell
protein
facilit
viral
replic
synthesi
neg
sens
rna
initi
posit
sens
rna
action
rdrp
follow
use
neg
sens
rna
templat
synthesi
new
genom
rna
sub
genom
rna
packag
new
virion
sub
genom
rna
translat
structur
protein
assembl
form
new
virion
capsid
assembl
structur
protein
packag
new
genom
rna
matur
virion
releas
cell
far
mechan
involv
viru
assembl
encapsid
releas
assembl
virion
complet
viral
life
cycl
poorli
understood
lead
difficulti
grow
calicivirus
gener
date
specif
antinoroviru
agent
nv
treatment
prophylact
purpos
avail
lack
nv
specif
vaccin
part
due
lack
robust
nv
anim
model
cell
cultur
assay
specif
human
noroviru
mnv
use
model
system
studi
hnv
mnv
use
infect
cell
produc
anim
model
sinc
mnv
close
relat
hnv
often
assum
activ
compound
mnv
system
similarli
activ
hnv
recent
howev
mnv
shown
imperfect
model
studi
hnv
due
differ
capsid
virus
enter
natur
hnv
influenc
cultiv
hnv
epitheli
cell
difficulti
produc
hnv
cell
line
like
due
problem
associ
purif
viru
particl
intern
viru
particl
cell
exampl
cellbas
fret
sensor
probe
specif
variou
noroviru
proteas
activ
cleav
variou
noroviru
cleavag
site
use
show
inde
differ
proteas
activ
specif
genogroup
ii
hnv
genogroup
v
mnv
work
develop
robust
hnv
cell
anim
model
thu
highli
relev
mark
breakthrough
studi
hnv
life
cycl
hnv
drug
develop
addit
anim
gnotobiot
gn
pig
evalu
use
model
studi
pathogenesi
hnv
well
test
antivir
hnv
sinc
pig
human
close
resembl
gastrointestin
anatomi
physiolog
immun
respons
shown
recent
howev
hnv
replic
moder
level
immort
b
cell
immunocompromis
mice
promis
research
could
open
door
develop
hnv
model
allow
detail
understand
hnv
lifecycl
studi
also
provid
basi
develop
hnv
cell
cultur
model
screen
new
hnv
inhibitor
comput
dock
experi
search
antinoroviru
agent
use
success
comput
dock
studi
identifi
polysulfon
naphthylurea
suramin
inhibit
rdrp
mnv
hnv
ic
valu
low
micromolar
rang
due
overal
neg
charg
inhibitor
cell
permeabl
poor
problem
address
employ
liposom
drug
deliveri
system
effect
inhibit
noroviru
replic
ec
valu
therapeut
index
found
microsecond
molecular
dynam
md
studi
rdrp
norwalk
viru
complex
natur
nucleosid
triphosph
substrat
cytidin
triphosph
ctp
chemic
modifi
deriv
report
backbon
sidechain
reson
assign
norwalk
viru
noroviru
strain
recent
solv
use
solut
nmr
spectroscopi
method
structur
assign
aid
studi
mechan
interact
proteas
substrat
inhibitor
noroviru
proteas
fluoresc
reson
energi
transfer
fret
assay
xray
crystallographi
nmr
spectroscopi
analysi
three
norwalk
viru
genogroup
genogroup
ii
murin
genogroup
v
perform
presenc
hit
proteas
inhibitor
protein
xray
crystallograph
data
provid
structur
inform
regard
noroviru
proteas
bind
interact
peptidyl
substrat
solut
nmr
structur
norwalk
viru
proteas
studi
show
exist
predominantli
monom
solut
overal
fold
noroviru
proteas
correspond
favor
report
protein
xray
crystal
structur
fuller
understand
structur
dynam
solut
may
aid
drug
discoveri
effort
may
elucid
mechan
lead
drug
resist
intern
hbga
exist
complex
carbohydr
coval
link
lipid
protein
surfac
mucos
epitheli
cell
well
red
blood
cell
bodili
fluid
blood
saliva
milk
intestin
liquid
found
free
oligosaccharid
differ
type
hbga
categor
accord
carbohydr
structur
nonreduc
end
oligosaccharid
exampl
type
b
h
lewi
antigen
known
type
subdivid
subtyp
sinc
host
hbga
main
cellular
receptor
viral
entri
cell
inhibit
viru
capsidhbga
bind
interact
would
result
blockag
viral
entri
host
cell
fact
b
cell
express
hbga
bacteria
intestin
prone
infect
noroviru
highresolut
protein
xray
crystal
structur
protrud
p
domain
noroviru
capsid
variant
rang
hbga
type
report
salivabas
enzym
immun
assay
effici
use
screen
librari
molecul
inhibitori
activ
block
noroviru
like
particl
hbga
receptor
report
crosssect
studi
children
perform
probe
associ
hbga
antigen
type
noroviru
infect
studi
examin
children
hospit
diarrhea
northern
vietnam
deem
hbga
secretor
partialsecretor
nonsecretor
result
show
link
host
cellular
hbga
express
noroviru
infect
electrospray
ioniz
mass
spectroscopi
esim
use
identif
quantif
carbohydrateprotein
interact
solut
method
known
catch
releas
car
esim
demonstr
identifi
high
affin
hbga
viruslik
particl
vlp
interact
method
involv
incub
noroviru
vlp
oligosaccharid
ligand
librari
librari
mani
molecul
follow
esim
analysi
ligand
bound
viru
vlp
show
molecular
weight
correspond
proteinligand
complex
mass
spectrum
mass
isom
ligand
could
distinguish
one
anoth
allow
ligand
dissoci
complex
releas
collisioninduc
dissoci
follow
highresolut
mass
analysi
case
ligand
bind
noroviru
vlp
affin
k
greater
carbohydr
assess
singl
caresim
experi
subvir
p
particl
noroviru
capsid
model
studi
virushbga
interact
employ
studi
screen
librari
preidentifi
bind
affin
confirm
assay
reliabl
librari
compound
screen
discov
new
carbohydr
bind
noroviru
vlp
protein
studi
found
seri
oligosaccharid
normal
found
cell
wall
mycobacteria
human
milk
bound
noroviru
pparticl
similar
bind
affin
known
hbga
receptor
moreov
sialic
acidcontain
gangliosid
also
serv
ligand
hnv
determin
caresim
experi
nmr
spectroscopi
provid
use
way
studi
molecular
interact
hbga
viral
capsid
observ
interact
synthesi
ligand
figur
coval
link
rigid
lanthanid
bind
tag
via
triazol
linker
carri
lanthanid
tag
fucos
allow
assign
protein
backbon
due
paramagnet
natur
lanthanid
ion
use
satur
transfer
differ
std
nuclear
overhaus
effect
noe
base
nmr
experi
employ
design
viral
entri
inhibitor
whole
viruslik
particl
two
polymer
inhibitor
polym
polym
figur
synthes
screen
competit
surfac
plasmon
reson
experi
polym
polym
show
promis
entryinhibitor
found
ic
valu
respect
std
nmr
spectroscopi
conjunct
transfer
noesi
experi
use
investig
bind
vlp
noroviru
strain
hbga
experi
involv
combin
synthet
hbga
saccharid
noroviru
vlp
monitor
overal
bind
pattern
std
nmr
spectroscopi
bind
confirm
presenc
std
signal
absenc
std
signal
indic
bind
interact
lfructos
recogn
bind
pocket
within
noroviru
vlp
bind
pocket
highli
conserv
across
broad
rang
noroviru
strain
suggest
hbgafructos
bind
pocket
promis
target
design
inhibitor
block
viral
entri
host
cell
infect
saliva
bind
assay
use
access
abil
variou
small
molecul
inhibit
interact
hbga
noroviru
vlp
found
compound
librari
inhibit
bind
interact
effect
three
repres
activ
molecul
depict
hbga
gii
noroviru
capsid
protein
xray
crystallographi
show
citrat
bound
noroviru
gii
capsid
domain
use
bind
interact
similar
observ
fucosehbga
bind
howev
case
citrat
bind
water
molecul
incorpor
bind
interact
form
ringlik
structur
mimic
pyranosid
ring
fucos
std
nmr
experi
show
citrat
bind
noroviru
capsid
domain
affin
similar
fucos
bind
htype
trisaccharid
bind
std
nmr
experi
suggest
citrat
bind
competit
hbga
noroviru
capsid
bind
citrat
citrat
deriv
could
use
antinoroviru
agent
interfer
hnvhbga
bind
thu
inhibit
viral
entri
cell
comput
model
experi
support
citrat
bind
p
domain
high
degre
mimicri
lfucos
esi
mass
spectrometri
techniqu
use
determin
intrins
bind
affin
per
bind
site
variou
hbga
ligand
hnv
vlp
subvir
p
particl
bind
affin
rang
found
interact
vlp
btype
triand
tetrasaccharid
hbga
bind
affin
rang
reveal
interact
subvir
p
particl
hbga
oligosaccharid
variou
epitop
b
h
diand
tetrasaccharid
differ
precursor
chain
type
singlecryst
xray
crystallographi
achiev
identifi
two
addit
fucos
bind
pocket
hnv
capsid
protrud
p
dimer
addit
site
term
site
locat
inbetween
two
previous
determin
lfucos
bind
site
cooper
bind
fucos
protrud
p
dimer
dose
depend
manner
observ
fucos
occupi
first
follow
fucos
lastli
site
biolog
relev
newli
identifi
site
remain
unknown
nmr
experi
use
confirm
noroviru
protrud
p
domain
inde
bind
hbga
cooper
multistep
process
nativ
mass
spectrometri
data
show
presenc
four
hbga
bind
site
per
pdimer
also
confirm
protein
xray
crystallograph
data
protrud
p
dimer
relat
noroviru
strain
data
highli
relev
research
group
studi
mechan
noroviru
entri
host
cell
specul
mechan
hbgacapsid
bind
may
alik
gener
calicivirida
viral
famili
fragmentbas
molecular
dock
approach
adapt
find
highaffin
fragment
bind
hbga
bind
pocket
bound
fragment
close
enough
link
togeth
occupi
differ
part
bind
site
propos
subsequ
four
molecular
structur
propos
shown
figur
howev
synthesi
biolog
evalu
report
comput
dock
virtual
screen
approach
autodock
softwar
discov
new
inhibitor
hbgacapsid
p
protein
bind
report
librari
million
molecul
gener
zinc
molecul
databas
screen
use
multistag
dock
protocol
hit
molecul
sever
molecul
block
hbga
bind
experiment
oligosaccharideand
salivabas
assay
ic
valu
less
three
activ
small
molecul
possess
cyclopenta
dimethylphenanthren
scaffold
thu
suggest
new
promis
scaffold
pursu
drug
design
effort
figur
protein
capsid
noroviru
genoclust
norwalk
shown
also
use
differ
bind
site
accommod
variou
ligand
comput
model
includ
molecular
mechan
molecular
dynam
glide
score
util
assess
clinic
import
broad
bind
specif
bind
site
provid
structur
insight
bind
differ
blood
type
b
saccharid
studi
show
fucos
bind
site
inde
favor
accommod
varieti
type
type
extend
abosaccharid
inhibitori
effect
varieti
chines
medicin
herb
bind
hbga
noroviru
protrus
p
protein
investig
seri
clinic
effect
herb
normal
activ
gastroenter
diseas
two
found
effect
prevent
hbga
p
protein
bind
chines
gall
pomegran
exhibit
ic
valu
type
saliva
type
b
saliva
respect
tannic
acid
suggest
activ
compon
two
herb
sinc
common
compon
herb
pure
tannic
acid
test
bind
inhibit
activ
good
inhibitori
activ
observ
ic
valu
b
type
saliva
two
structur
protein
encod
noroviru
genom
capsid
protein
minor
structur
protein
major
structur
protein
contain
shell
domain
protrud
domain
pd
divid
two
subdomain
subdomain
locat
outermost
surfac
viral
capsid
compris
bind
surfac
host
hbga
receptor
larg
degre
conserv
capsid
interact
surfac
prompt
antivir
approach
focu
design
specif
molecul
howev
report
target
structur
protein
appear
may
due
limit
inform
associ
attach
host
cell
entri
process
viral
surfac
protein
undergo
mutat
allow
resist
strain
emerg
target
nonstructur
proteinsa
describ
target
structur
protein
may
result
develop
viral
resist
henc
viral
nonstructur
protein
well
conserv
region
along
critic
function
may
repres
benefici
target
detail
review
describ
function
noroviru
nonstructur
protein
report
sinc
human
lack
rdrp
enzym
enzym
consid
one
promis
target
antinoroviru
drug
develop
includ
noroviru
proteas
cleav
long
polypeptid
chain
translat
viral
rna
multipl
nonstructur
protein
serv
import
enzym
support
noroviru
life
cycl
date
numer
research
group
studi
cleavag
noroviru
polyprotein
viru
proteas
common
approach
involv
use
fret
peptid
substrat
vitro
assay
analysi
infect
cell
lysat
use
western
blot
experi
luciferasebas
incel
assay
despit
result
substrat
studi
avail
protein
xray
crystal
structur
hnv
mnv
proteas
enzym
noroviru
proteas
substrat
specif
fulli
understood
recent
properti
hnv
proteas
eukaryot
system
context
full
polyprotein
translat
difficult
assess
due
lack
robust
hnv
cell
cultur
system
improv
assay
system
allow
studi
proteas
cleavag
multipl
cleavag
site
complet
polyprotein
express
transient
yet
simpl
system
contain
mammalian
cell
report
order
aid
studi
hnv
replic
cell
cultur
novel
gaussia
luciferasebas
hnv
report
system
also
use
effici
assay
screen
proteas
inhibitor
shown
xray
crystallograph
data
show
noroviru
proteas
chymotrypsinlik
proteas
activ
site
consist
three
import
aminoacid
residu
detail
mechan
proteas
cleavag
report
develop
peptidyl
proteas
inhibitor
michael
acceptor
cterminu
led
discoveri
mani
antivir
compound
promis
vitro
vivo
antivir
activ
michael
acceptor
moieti
allow
coval
irrevers
bind
inhibitor
enzym
activ
site
via
nucleophil
attack
cystein
thiol
function
onto
michael
acceptor
first
protein
xray
crystal
structur
southampton
noroviru
proteas
bound
polypeptid
irrevers
inhibitor
publish
michael
acceptor
moieti
employ
ene
ester
figur
structur
bind
inform
obtain
data
provid
foundat
current
knowledg
regard
design
subsequ
antinoroviru
inhibitor
rupintrivir
possess
similar
ene
ester
function
known
enteroviru
proteas
inhibitor
also
activ
mnv
hnv
thu
show
excel
broadspectrum
antinoroviru
activ
design
synthesi
biolog
activ
seri
optim
dipeptidyl
inhibitor
noroviru
report
structureactivityrelationship
approach
along
xray
crystallographi
use
design
inhibitor
mnv
vivo
assay
use
screen
activ
gener
structur
dipeptidyl
inhibitor
shown
figur
contain
r
substitut
benzyloxycarbonyl
group
ntermin
cap
amino
acid
residu
side
chain
r
glutamin
surrog
posit
ctermin
warhead
x
aldehyd
one
activ
compound
r
mcl
r
cyclohexylalanin
x
aldehyd
exhibit
potent
inhibitori
activ
enzym
assay
ic
noroviru
repliconcellbas
assay
ec
nm
compound
effect
reduc
noroviru
titer
mice
small
larg
intestin
mice
show
reduct
respect
viral
titer
day
post
viral
infect
compar
control
group
activ
site
calicivirida
share
sequenc
structur
similar
proteas
coronavirida
picornavirida
seri
dipeptidyl
inhibitor
evalu
activ
variou
calicivirida
coronavirida
picornavirida
famili
use
proteas
enzym
assay
andor
cellbas
assay
two
test
compound
show
excel
broadspectrum
antivir
activ
ic
valu
low
micromolar
high
nanomolar
rang
virus
screen
except
hav
felin
calicivirus
fcv
seri
novel
tripeptidyl
inhibitor
noroviru
proteas
effect
inhibit
noroviru
proteas
enzym
assay
viral
replic
noroviru
repliconcellbas
assay
report
figur
gener
structur
tripepidyl
inhibitor
contain
ntermin
cbz
cap
arylalanin
leucin
glutamin
surrog
ctermin
warhead
noroviru
proteas
quit
specif
ident
substrat
amino
acid
side
chain
requir
either
gln
q
glu
e
posit
higher
toler
chang
substrat
posit
number
potent
inhibitor
report
ic
valu
rang
ec
valu
rang
notabl
tripeptidi
seri
requir
hydrophob
arylalanin
posit
necessit
good
cell
base
inhibitori
activ
suggest
improv
cell
membran
permeabl
promis
compound
compound
ic
valu
ec
valu
nm
bisulfit
adduct
shown
act
prodrug
convert
back
aldehyd
warhead
function
vivo
also
explain
analog
ec
valu
compound
compound
cell
base
assay
nm
recent
studi
show
compound
structur
analogu
highli
efficaci
antivir
agent
felin
coronavirus
fcov
fcv
cell
cultur
ec
valu
low
micromolar
rang
suggest
compound
potenti
develop
therapeut
agent
fcov
fcv
virus
domest
wild
cat
structureact
relationship
studi
seri
peptidomimet
proteas
inhibitor
report
conclud
role
structur
side
chain
import
achiev
good
activ
role
side
chain
play
minor
role
bind
potent
tripeptidyl
inhibitor
aldehyd
moieti
ctermin
end
act
electrophil
react
form
reversiblecoval
bond
class
inhibitor
therefor
competit
natur
substrat
activ
site
bind
known
macrocycl
peptid
may
offer
advantag
linear
peptid
term
druglik
characterist
less
prone
proteolysi
repres
macrocycl
peptidyl
compound
figur
synthes
util
side
chain
effect
lock
peptid
conform
macrocycl
peptid
screen
antinoroviru
activ
enzym
cell
base
assay
molecul
show
good
inhibit
activ
enzym
assay
ic
howev
show
inhibitori
activ
concentr
rang
test
cellbas
assay
ester
activ
enzym
cellbas
assay
suggest
ester
function
poor
ctermin
warhead
seri
macrocycl
proteas
inhibitor
investig
two
compound
show
promis
cellbas
antinoroviru
activ
ec
valu
respect
deriv
compound
triazol
show
broadspectrum
antivir
activ
ic
enteroviru
nanci
strain
ic
sarscov
ic
comput
dock
studi
perform
order
gain
understand
bind
macrocycl
inhibitor
differ
proteas
enzym
viral
encod
rna
depend
rna
polymeras
rdrp
key
target
design
antinoroviru
therapeut
due
vital
role
replic
noroviru
genom
absenc
homolog
human
enzym
rdrp
carri
synthesi
genom
subgenom
rna
norovirus
infect
host
recombin
rdrp
use
elucid
biochem
properti
xray
crystal
structur
rdrp
human
norwalk
virus
gi
gii
mous
gv
norovirus
reveal
detail
inform
activ
site
rdrp
studi
rdrp
inhibitor
divid
two
categori
nucleosid
inhibitor
nonnucleosid
inhibitor
upon
penetr
cell
nucleosid
inhibitor
undergo
phosphoryl
triphosph
give
nucleotid
incorpor
polymer
nucleic
acid
chain
elong
rdrp
subsequ
includ
grow
rna
chain
result
termin
replic
elong
step
nonnucleosid
inhibitor
potenti
bind
one
sever
alloster
site
rdrp
enzym
therebi
induc
conform
chang
enzym
lead
inhibit
initi
step
rna
replic
silico
screen
well
vitro
enzym
assay
led
identif
variou
inhibitor
noroviru
rdrp
suramin
figur
inhibitor
variou
dnarna
polymeras
analog
inhibit
mnv
hnv
rdrp
ic
valu
nanomolar
rang
howev
two
compound
naphthalenetrisulfon
acid
head
display
poor
membran
permeabl
subsequ
tetrasodium
salt
ppnd
known
specif
receptor
antagonist
low
micromolar
ic
valu
mnv
rdrp
vitro
discov
crystal
structur
rdrp
suramin
ppnd
determin
found
ppnd
bind
differ
site
rdrp
distinct
occupi
suramin
addit
figur
hepat
c
viru
inhibitor
also
inhibit
vitro
replic
mnv
ec
norwalk
replicon
cell
system
ec
furthermor
reduc
viral
shed
transmiss
uninfect
mice
experi
perform
mous
model
valu
ccid
cell
cultur
infecti
dose
sever
small
molecul
nonnucleosid
inhibitor
rdrp
transcript
found
high
throughput
screen
follow
radioact
nucleotid
incorpor
rdrp
assay
phenylthiazol
carboxamid
pyrazol
acetamid
triazol
pyrazolidinedion
ic
valu
respect
found
figur
addit
favipiravir
ribavirin
also
inhibit
rdrp
vitro
moreov
crystal
structur
mnv
polymeras
bound
activ
compound
ribavirin
suramin
suramin
analog
examin
thu
provid
use
insight
bind
site
inhibitor
antinoroviru
activ
chromon
e
assess
mnv
assay
surrog
model
hnv
hit
molecul
e
e
exhibit
promis
ic
valu
low
micromolar
rang
figur
although
mechan
action
known
author
hypothes
compound
may
target
noroviru
polymeras
enzym
repres
rdrp
inhibitor
report
list
figur
recent
small
molecul
deubiquitinas
dub
inhibitor
found
show
promis
antiinfect
activ
hnv
mnv
studi
stem
earlier
report
dub
inhibitor
show
antinoroviru
activ
antiinfect
activ
foodborn
pathogen
well
anticanc
activ
limit
use
due
poor
oral
bioavail
low
water
solubl
therefor
subject
ration
drug
design
approach
search
improv
dub
inhibitor
studi
prompt
identif
promis
drug
candid
compound
screen
librari
molecul
use
norwalk
viru
replicon
system
compound
decreas
viral
titer
cell
treat
hour
concentr
compar
control
quantif
norwalk
viru
genom
use
qrtpcr
compound
decreas
level
detect
norwalk
viru
genom
ubiquitin
dub
enzym
becom
recogn
interest
target
therapeut
drug
develop
howev
dub
inhibitor
reach
clinic
trial
date
hope
hit
molecul
optim
discov
improv
antiinfect
agent
norovirus
broadspectrum
activ
role
dub
play
modul
norovir
infect
remain
poorli
understood
suggest
dub
inhibit
induc
unfold
protein
respons
upr
block
noroviru
infect
norovirus
highli
variabl
genom
distinct
virus
alreadi
identifi
diverg
nucleotid
sequenc
among
five
known
genogroup
shown
howev
noroviru
genom
conserv
region
norovir
rna
share
sequenc
similar
viral
subgenom
rna
interact
start
target
norovir
mrna
design
phosphorodiamidi
morpholino
oligom
pmo
norovir
replic
inhibitor
due
abil
pmo
bind
norovir
mrna
watsoncrick
basepar
caus
steric
blockad
inhibit
replic
propos
design
pmo
neutral
backbon
stabl
use
morpholin
ring
place
deoxyribos
sugar
pmo
also
conjug
arginin
rich
cellpenetr
peptid
peptidepmo
ppmo
improv
cellular
uptak
cell
seri
ppmo
present
dose
respons
uptak
ppmo
macrophag
exhibit
zero
cellular
toxic
concentr
toxic
ppmo
two
test
ppmo
b
cgttgccatcctcatttcac
c
cgcagaagatggcgttgccatcctc
design
target
inhibit
viru
replic
least
maxim
nontox
concentr
use
assay
ic
valu
activ
ppmo
found
b
ic
compound
c
found
acylcoenzym
cholesterol
acyltransferas
acat
found
upregul
noroviru
repliconharbor
cell
commerci
avail
acat
inhibitor
shown
inhibit
noroviru
infect
henc
seri
pyranobenzopyron
inhibit
noroviru
investig
like
acat
inhibit
host
cell
two
repres
molecul
figur
show
best
antinoroviru
activ
ec
valu
respect
therapeut
index
valu
greater
compound
screen
activ
use
noroviru
replicon
harbor
cellbas
assay
inhibit
reveal
reduct
noroviru
rna
replic
result
demonstr
acat
host
cell
could
target
antinoroviru
drug
develop
optim
inhibitor
may
lead
hit
molecul
far
specif
antinoroviru
drug
vaccin
proceed
clinic
trial
phase
howev
nitazoxanid
figur
origin
develop
commerci
antiprotozo
agent
shown
reduc
resolut
symptom
median
time
first
dose
resolut
symptom
day
compar
placebo
day
patient
least
year
age
mean
year
infect
rotaviru
p
noroviru
p
anoth
case
report
indic
treatment
nitazoxanid
immunocompromis
patient
histori
noroviru
infect
shown
declin
bowel
movement
approxim
bowel
movement
per
day
hour
consist
frequenc
bowel
movement
return
baselin
day
treatment
addit
molecul
shown
efficaci
toward
diarrhea
caus
rotaviru
infect
data
provid
ration
design
new
class
compound
thiazolid
noroviru
infect
overview
discoveri
inhibitor
noroviru
describ
includ
inhibit
structur
nonstructur
noroviru
protein
viral
entri
host
cell
number
low
nanomolar
inhibitor
discov
though
pass
decad
sinc
discoveri
norwalk
replicon
cell
line
yet
fda
approv
antinoroviru
drug
vaccin
avail
lack
human
noroviru
cell
line
understand
mechan
encapsid
cell
exit
pathway
like
hinder
drug
develop
current
antinoroviru
drug
discoveri
mainli
focus
approach
relat
viral
target
rna
depend
rna
polymeras
noroviru
proteas
structur
protein
extent
abl
identifi
sever
lead
compound
potenti
antinoroviru
activ
vitro
vivo
howev
none
proceed
level
clinic
use
treatment
prevent
noroviru
infect
part
due
bioavail
efficaci
possibl
safeti
issu
illustr
necess
develop
safe
efficaci
antinoroviru
therapeut
improv
bioavail
fact
potenti
antinoroviru
molecul
mainli
target
pathogen
intestin
effect
deliveri
inhibitor
site
action
toler
compound
rather
harsh
condit
make
need
better
optim
necessari
number
peptidyl
compound
possess
strong
antivir
proteas
activ
vitro
nanomolar
inhibitori
activ
issu
low
bioavail
vivo
due
rapid
metabol
variou
proteas
bodi
hamper
progress
molecul
therefor
optim
efficaci
current
compound
medicin
approach
like
modif
inhibitor
without
peptidyl
structur
possess
noncleav
peptidyl
structur
appear
challeng
reward
rout
notabl
key
target
viral
polymeras
viral
entri
host
receptor
along
host
chaperon
protein
belong
hsp
famili
proper
proteas
fold
proteolysi
import
need
explor
search
potent
drug
candid
low
toxic
believ
combin
small
molecul
inhibit
viral
proteas
polymeras
blockag
viral
entri
inhibit
viral
entri
protein
capsid
protein
would
provid
effect
counteract
viru
infect
continu
interest
explor
target
host
factor
inherit
host
variabl
overcom
develop
resist
mutat
identifi
understand
host
factor
detail
contribut
viru
replic
insid
host
may
provid
new
target
facilit
discoveri
antivir
compound
less
chanc
resist
develop
sinc
treatment
period
short
four
five
day
toxic
would
minor
issu
healthi
adult
infect
noroviru
henc
target
viral
factor
host
factor
equal
import
fact
critic
immunecompromis
elderli
patient
infect
norovirus
need
prolong
treatment
period
therefor
essenti
develop
safe
effect
antinoroviru
therapeut
especi
popul
futur
prospect
search
safe
efficaci
drug
candid
like
base
current
tool
avail
field
key
find
find
human
norovirus
replic
b
cell
mnv
anim
model
noroviru
replicon
cell
line
illumin
aspect
relat
viru
replic
infect
vivo
laid
groundwork
understand
vivo
viru
host
interact
fundament
aspect
immun
viral
pathogenesi
extent
moreov
cell
system
anim
model
avail
initi
screen
confirm
efficaci
discov
hit
molecul
hurdl
field
noroviru
drug
discoveri
develop
fulli
permiss
cell
cultur
system
small
anim
model
human
norovirus
use
studi
variou
aspect
diseas
identifi
human
numer
research
effort
go
achiev
goal
anoth
major
issu
particularli
import
field
proper
elucid
molecular
mechan
associ
noroviru
genom
translat
replic
use
norovirus
elicit
enter
patholog
area
fulli
understood
would
interest
studi
ongo
futur
research
may
hope
overcom
limit
inabl
cultiv
human
noroviru
vitro
lead
identif
success
drug
candid
develop
vaccin
counteract
noroviru
like
explor
come
year
structur
lfucosetag
polym
polym
lfucos
citrat
four
comput
gener
hbga
inhibitor
